Irish Pharmaceutical Healthcare Association

Lobbying Organisation Irish Pharmaceutical Healthcare Association

Date published 20 May, 2022

Relevant Matter Public policy or programme

Public Policy Area Health

Period 1 Jan, 2022 to 30 Apr, 2022

Specific Details (i) EU Pharmaceutical Policy; (ii) EFPIA WAIT Indicator Survey - Access to new medicines; (iii) Access to Orphan Medicines; (iv) EU Pharmaceutical Strategy

Intended results (i) Government support for improved access to new medicines. (ii) Reduce the time for access to new medicines from Irish average 541 days to Irish and European set standard of 180 days (iii) Government support for improved access to Orphan Medicines (iv) Government support for innovation in the context of the EU Pharmaceutical Strategy

Name of person primarily responsible for lobbying on this activity Oliver O'Connor

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) Yes

Current or Former Designated Public Official(s)

Oliver O'Connor (Former DPO) Special Adviser (Department of Jobs, Enterprise and Innovation)

Oliver O'Connor (Former DPO) Special Adviser (Department of Health)

Bernard Mallee (Former DPO) Special Adviser (Department of Education and Skills)

Bernard Mallee (Former DPO) Special Adviser (Department of Jobs, Enterprise and Innovation)

Jim McGrath (Former DPO) Special Adviser (Department of Environment, Community and Local Government)

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Letter (1)

EU Pharmaceutical Policy. (i) Government support for improved access to new medicines.

Email (1)

EFPIA Patient WAIT Indicator Survey - Access to new medicines. (ii) Reduce the time for access to new medicines from Irish average 541 days to Irish and European set standard of 180 days.

Virtual Meeting (1)

Access to Orphan Medicines (iii) Government support for improved access to Orphan Medicines

Virtual Meeting (2-5)

EU Pharmaceutical Strategy (iv) Government support for innovation in the context of the EU Pharmaceutical Strategy

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Stephen Donnelly Minister (Department of Health)

David Cullinane TD (Dáil Éireann, the Oireachtas)

Pádraig O'Sullivan TD (Dáil Éireann, the Oireachtas)

Deirdre Clune MEP (European Parliament)

Billy Kelleher MEP (European Parliament)